![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Warns Compounder Over Unsterile Procedures, GMP Failures
FDA Warns Compounder Over Unsterile Procedures, GMP Failures
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/MeasuringRiskwithTapeMeasure.gif?t=1493076129&width=430)
The FDA sent a warning letter to Ranier’s Compounding Laboratory, based in Jeannette, Pa., noting serious deficiencies in sterile procedures and GMPs.
The agency initially issued a Form 483 after an April 2016 inspection but was not satisfied with the response. FDA investigators said Ranier’s did not receive valid prescriptions for individually identified patients for a portion of the products and produced drug products in violation of the FDCA.
The firm said it would cease compounding office-use-only products for physicians, but the FDA said it was unable to fully evaluate the corrective actions because of a lack of supporting documentation.
Investigators also noted that sterile drug products were prepared, packed or held under unsanitary conditions: aseptic operators placed their ungloved hands into the ISO 5 hood and failed to sanitize their gloved hands after touching non-sterile components.
Upcoming Events
-
21Oct